LABS Inc. Acquisition of Assets of Laboratories at Bonfils is Finalized
DENVER--(Business Wire)--LABS Inc. has finalized the agreement to acquire the assets of Laboratories at Bonfils - a subsidiary of Bonfils blood center. The parties closed the final agreement on November 30th, 2007. LABS Inc. is the Country's leading testing facility for the specialized needs of organ procurement organizations, eye and tissue banks. LABS Inc. will continue to provide donor eligibility testing for the human eye, tissue, reproductive, stem cell and solid organ transplant industry. "LABS Inc. will continue to provide the most accurate, high-quality and timely testing methods for the transplant community," said Elizabeth Hearty, chief executive officer of LABS Inc. "We look forward to working with industry leaders in a consultative and partnering manner to consistently improve the delivery and efficiency of our quality laboratory services for organizations across the country." LABS Inc. is a nonprofit, taxable affiliate of AlloSource, a Colorado-based, nonprofit provider of bone and soft tissue allografts to local communities. LABS Inc. retains its own management team reporting to an independent board of directors. All current Laboratories at Bonfils staff, including senior management, PhDs and highly qualified laboratory personnel, have been retained by LABS Inc. to continue to provide unparalleled consultative expertise and industry knowledge to customers. About LABS Inc. LABS Inc., based in Denver, Colorado, is one of the premier transplant medicine reference laboratories in the country. Testing is focused on donor eligibility determination and final product safety, infectious disease testing, microbiology, histocompatibilty and environmental monitoring. LABS Inc. is committed to respectfully fulfilling the wishes of donors by ensuring the gift is able to generate positive patient outcomes. LABS Inc. employs over 100 people. For LABS Inc. Jennifer Tramontana, 303-929-9636 jennifer@fletchergroupllc.com Copyright Business Wire 2007
© Thomson Reuters 2009 All rights reserved




